Global qPCR and dPCR Instrumentation Industry

Global qPCR and dPCR Instrumentation Industry

  • July 2022 •
  • 573 pages •
  • Report ID: 1921269 •
  • Format: PDF

What`s New for 2022?
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to our digital archives and MarketGlass Research Platform
- Complimentary updates for one year

Global qPCR and dPCR Instrumentation Market to Reach $9.2 Billion by 2026
- Real-Time PCR also referred to as Quantitative PCR (qPCR) analysis, is a modification of the traditional PCR technique. In traditional Polymerase Chain Reaction (PCR), the amplified DNA product or amplicon is detected in an end-point analysis by visualization of the DNA product on an agarose gel subsequent to completion of the reaction, which comprises a specified number of amplification cycles. In real-time PCR, however, the accumulation of amplification product is evaluated simultaneously with the progress of the reaction. Product quantification is carried out in real time, after every cycle. Digital PCR (dPCR) is an improvement of traditional PCR methods and is utilized to directly quantify as well as clonally amplify nucleic acids such as DNA, RNA, cDNA or methylated DNA. However, digital PCR is at an early stage. The main difference between conventional PCR and dPCR lies in the method used to measure amounts of nucleic acids. Sensitivity of dPCR is high in comparison to qPCR, hence, the technology is particularly used in applications wherein there is a low amount of target sequence. For instance, mutation genes that are found on a very low scale in rare diseases, and HIV DNA that are present in 1,000-10,000 in number within the cell of a patient can be easily detected through the technology.
- Amid the COVID-19 crisis, the global market for qPCR and dPCR Instrumentation estimated at US$7.1 Billion in the year 2022, is projected to reach a revised size of US$9.2 Billion by 2026, growing at a CAGR of 9.8% over the analysis period. qPCR, one of the segments analyzed in the report, is projected to grow at a 9.3% CAGR to reach US$8.4 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the dPCR segment is readjusted to a revised 13% CAGR for the next 7-year period. This segment currently accounts for a 12.5% share of the global qPCR and dPCR Instrumentation market. Higher user-familiarity with existing qPCR equipment, as well as the availability of new and refurbished qPCR instruments at affordable prices continues to support growth in the qPCR market. Growth in the market is fueled by strong demand for these solutions in analysis of gene expression and genotyping as an effective validation tool. Superior accuracy and ability to deliver results faster, qPCR is finding increasing adoption among biopharmaceutical and educational organization laboratories. The dPCR technology has gained a considerable attention in the recent years owing to its ability to provide superior accuracy and higher levels of sensitivity. Technological advancements, rising aging population, growing incidents of genetic disorders and infectious diseases, and increasing private-public grants and investments are propelling their advancements and adoption. In addition, the dPCR technology continues to garner a significant attention owing to increasing integration with robotics.

The U.S. Market is Estimated at $2.2 Billion in 2022, While China is Forecast to Reach $742.3 Million by 2026
- The qPCR and dPCR Instrumentation market in the U.S. is estimated at US$2.2 Billion in the year 2022. The country currently accounts for a 30.8% share in the global market. China, the world`s second largest economy, is forecast to reach an estimated market size of US$742.3 Million in the year 2026 trailing a CAGR of 12.2% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.1% and 8.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.1% CAGR while Rest of European market (as defined in the study) will reach US$813.9 Million by the close of the analysis period.
- While Europe is another large market for qPCR and dPCR instrumentation, growth worldwide is projected to be spearheaded by Asia-Pacific. In terms of concentration, a large number of leading companies are located in the US and Europe. However, increasing competition in the markets over the last few years has been driving various players to shift their attention to other promising regions including Latin America and Asia-Pacific. In Asia-Pacific, growth is led by the increased use of qPCR in blood donor testing & screening and diagnosis of infectious diseases and tropical diseases such as Malaria. Increasing geriatric population and the resulting incidents of chronic medical conditions such as cancer coupled with broader application of PCR to study mutations and gene anomalies related to these diseases are driving adoption. Falling cost of nucleic acid detection, quantification, and amplification techniques will additionally encourage adoption of qPCR and dPCR instrumentation in research and diagnosis, particularly in developing, resource poor countries. Asia-Pacific has been witnessing increasing focus of PCR solution suppliers to establish or expand their production and sales network in the region. In the recent years, various vendors have shifted their manufacturing units to the region for enjoying cost benefits and accessing domestic markets, which in turn is increasing awareness of the technology in the region, contributing to growth in the market.

Select Competitors (Total 74 Featured) -
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • BioFire Diagnostics, Inc.
  • Bio-Rad Laboratories, Inc.
  • Cepheid
  • Eppendorf AG
  • F. Hoffmann-La Roche Ltd.
  • Fluidigm Corporation
  • Promega Corporation
  • Takara Bio, Inc.
  • Thermo Fisher Scientific Inc.